← All trials
NCT05419427
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2021
- Primary completion
- Sep 11, 2024
- Completion date
- Nov 24, 2024
- First posted
- Jun 15, 2022
- Last posted
- Aug 18, 2022
- Enrollment
- 552
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lambda Therapeutic Research LtdLead sponsor
- Intas Pharmaceuticals LimitedCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.